Pulse Biosciences Grants Equity Incentive Awards to New Employees
April 15 2019 - 5:00PM
Business Wire
Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or
the “Company”), a novel medical therapy company bringing to market
its proprietary CellFX™ System, announced today that the
Compensation Committee of the Company’s Board of Directors granted
non-qualified stock options covering an aggregate of 28,000 shares
of Pulse Biosciences common stock to three new non-executive
employees under the Pulse Biosciences 2017 Inducement Equity
Incentive Plan on April 15, 2019.
The 2017 Inducement Equity Incentive Plan is used exclusively to
grant equity awards to individuals who were not previously an
employee or non-employee director of Pulse Biosciences as an
inducement material to such individual’s entering into employment
with Pulse Biosciences in accordance with Nasdaq Marketplace Rule
5635(c)(4).
The options have an exercise price of $16.02 per share, which is
equal to the closing price of Pulse Biosciences common stock on
April 15, 2019. The 28,000 shares underlying the option grants will
vest and become exercisable as to 25% of the shares annually
beginning on the first anniversary of the recipient’s start date,
subject to the recipient’s continued employment with Pulse
Biosciences on these vesting dates. The options are subject to the
terms and conditions of the 2017 Inducement Equity Incentive Plan
and the award agreements entered into with each recipient.
About Pulse Biosciences
Pulse Biosciences is a novel medical therapy company
bringing to market its proprietary CellFX™ System. The Company’s
novel CellFX System provides a precise, non-thermal delivery of
nanosecond duration energy pulses that impact cells in treated
tissue while sparing non-cellular tissue. This unique mechanism of
action disrupts the functions of internal cell structures while
maintaining the outer cell membrane, initiating a cascade of events
within the cell that results in regulated cell death. The novel
characteristics of the Company’s CellFX System has the potential to
significantly benefit patients across multiple medical
applications, including dermatology, the Company’s first planned
commercial application. In pre-clinical studies, Nano-Pulse
Stimulation™ (NPS™) technology platform has demonstrated an ability
to induce immunogenic cell death in several cancer cell lines. The
Company believes its NPS technology platform may play a role in
immuno-oncology as a focal tumor treatment that can initiate an
adaptive immune response. More information can be found
at www.pulsebiosciences.com.
Caution: Pulse Biosciences’ CellFX system and Nano-Pulse
Stimulation (NPS) are for investigational use.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190415005855/en/
Investor Relations:Pulse Biosciences, Inc.Brian DowSr.
Vice President and Chief Financial
OfficerIR@pulsebiosciences.com
or
Solebury TroutGitanjali Jain Ogawa,
646-378-2949gogawa@troutgroup.com
Media:Tosk CommunicationsNadine D. Tosk,
504-453-8344nadinepr@gmail.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Apr 2023 to Apr 2024